Who are Placebo then Pioglitazone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): pioglitazone + simvastatin, Dapagliflozin + Lobeglitazone, Pioglitazone and Metformin, Pioglitazone vs Metformin, Actos (Pioglitazone), alogliptin + pioglitazone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-then-pioglitazone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Placebo then Pioglitazone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo then Pioglitazone (Placebo then Pioglitazone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thiazolidinedione. Area: Diabetes.

marketed Thiazolidinedione PPAR-γ (Peroxisome proliferator-activated receptor gamma) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Placebo then Pioglitazone (Placebo then Pioglitazone) — Medical University of South Carolina. Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo then Pioglitazone TARGET	Placebo then Pioglitazone	Medical University of South Carolina	marketed	Thiazolidinedione	PPAR-γ (Peroxisome proliferator-activated receptor gamma)
pioglitazone + simvastatin	pioglitazone + simvastatin	University of Leipzig	marketed	Thiazolidinedione + HMG-CoA reductase inhibitor combination	PPAR-γ (pioglitazone); HMG-CoA reductase (simvastatin)
Dapagliflozin + Lobeglitazone	Dapagliflozin + Lobeglitazone	Seoul National University Bundang Hospital	marketed	SGLT2 inhibitor + thiazolidinedione combination	SGLT2 and PPAR-γ
Pioglitazone and Metformin	Pioglitazone and Metformin	Takeda	marketed	Thiazolidinedione + Biguanide combination	PPAR-γ (pioglitazone); Complex I of mitochondrial respiratory chain (metformin)
Pioglitazone vs Metformin	Pioglitazone vs Metformin	Post Graduate Institute of Medical Education and Research, Chandigarh	marketed	Antidiabetic agents (thiazolidinedione vs. biguanide)	Pioglitazone: PPAR-γ; Metformin: AMPK
Actos (Pioglitazone)	Actos (Pioglitazone)	Taipei Veterans General Hospital, Taiwan	marketed	Thiazolidinediones	PPAR-γ
alogliptin + pioglitazone	alogliptin + pioglitazone	Kun-Ho Yoon	marketed	DPP-4 inhibitor + thiazolidinedione	DPP-4 and PPAR-γ

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thiazolidinedione class)

Merck Sharp & Dohme LLC · 3 drugs in this class
GlaxoSmithKline · 1 drug in this class
Medical University of South Carolina · 1 drug in this class
National Cheng-Kung University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo then Pioglitazone — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-then-pioglitazone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab